Biotechnology
Technology
Health
Compugen
$3.779876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.07 (1.89%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Compugen and other stocks, options, ETFs, and crypto commission-free!
About
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. Read More The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Employees
101
Headquarters
Holon, Tel Aviv
Founded
1993
Market Cap
211.63M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
204.98K
High Today
$3.81
Low Today
$3.68
Open Price
$3.70
Volume
64.64K
52 Week High
$5.00
52 Week Low
$2.00
Collections
Biotechnology
Technology
Health
Research And Development
Asia (Non-China)
Asia
Female CEOs
News
PR NewswireMar 12
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
HOLON, Israel, March 12, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted two composition of matter patents for COM701, the Company's lead immuno-oncology therapeutic antibody candidate. One patent covers the composition of COM701 and backup antibodies, while the second patent covers the composition of any antibody having the fragme...
Price Paid on Robinhood
4% Higher
Right Now
52 Week Low
$2.00
Average Price Paid
$3.62
52 Week High
$5.00
Earnings
-$0.19
-$0.13
-$0.06
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 8, Pre-Market